LYO-X AG

LYO-X provides strategic consulting and PK/PD modelling services dedicated to the preclinical and clinical development of biologics and cell based therapies. Our speciality are drug formats at the scientific edge: bi-specifics, antibody-drug conjugates, scFvs, nanobodies and cell based therapies. Whatever your therapeutic approach, we have the expertise in biology, pharmacology, mathematical modeling and drug development to provide tailored support for your unique program. We apply systems pharmacology for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, dose / regimen finding studies and paediatric drug development....

Systems pharmacology,pk/pd,biotherapeutics,paediatric drug development,bi specifics,antibodies,cell based therapies,first in human dose selection,target mediated drug disposition,and modeling and simulation

Lyo-x ag operates in the Biotechnology research industry.

Lyo-x ag's revenue is 11m - 100m

Lyo-x ag has 11 - 50 employees.